Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

Fig. 1

Chimaeric RHDV VLP Containing CRC TAAs. Each chimaeric RHDV VLP construct was expressed in Sf21 cells and purified for analysis and applications in vaccination. a Diagram outlining the structure of the recombinant VP60 produced for each chimaeric VLP construct, including non-mutant H-2Kb restricted peptide sequences, ALL linker and GGS spacer sequence. b Western blot probing for RHDV VP60 with T.VP60, S.VP60 and TS.VP60 represented in comparison to unmodified VP60. Electron microscopy was used to identify the formation of intact VLP from the expression of c T.VP60, d S.VP60 and e TS.VP60

Back to article page